Amgen Wins Approval for Pathbreaking Lung Cancer Drug – The Wall Street Journal
Business News
- Amgen Wins Approval for Pathbreaking Lung Cancer Drug The Wall Street Journal
- FDA approves Amgen drug for lung cancer with specific mutation CNBC
- FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy PRNewswire
- Amgen Lung-Cancer Drug That Targets Mutation Cleared in U.S. Bloomberg
- How a protein ‘Polaroid’ led Amgen to finally crack the ‘Achilles heel tumor’ with Lumakras in 8 years FierceBiotech
- View Full Coverage on Google News
Source: Business News